|
1
|
Global Initiative for Asthma. Global
strategy for asthma management and prevention, 2021. Available
from: https://ginasthma.org/gina-reports/. Accessed August
12, 2021.
|
|
2
|
The Global Asthma Report 2018. Auckland,
New Zealand: Global asthma network. Available from: https://theunion.org/technical-publications/the-global-asthma-report-2018
http://globalasthmanetwork.org/.
Accessed December 13, 2020.
|
|
3
|
D'Amato G, Vitale C, Molino A, Stanziola
A, Sanduzzi A, Vatrella A, Mormile M, Lanza M, Calabrese G,
Antonicelli L and D'Amato M: Asthma-related deaths. Multidiscip
Respir Med. 11(37)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
GINA Pocket Guide 2019. Difficult to treat
and severe asthma in adults and adolescents. Available from:
https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf.
Accessed September 10, 2020.
|
|
5
|
Munteanu LA, Fildan AP, Tudorache E,
Fira-Mladinescu O, Frandes M, Timar B, Oancea C and Tofolean DE:
Inhaler technique errors in Romanian patients with asthma-a
multicenter study. Patient Prefer Adherence. 13:1401–1414.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pavord ID, Shrimanker R and Hanania NA:
Biologics targeting type 2 inflammation. In: Severe Asthma (ERS
Monograph). Chung KF, Israel E and Gibson PG (eds). European
Respiratory Society, Sheffield, pp285-303, 2019.
|
|
7
|
Busse WW: Biological treatments for severe
asthma: A major advance in asthma care. Allergol Int. 68:158–166.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Robinson D, Humbert M, Buhl R, Cruz AA,
Inoue H, Korom S, Hanania NA and Nair P: Revisiting type 2-high and
type 2-low airway inflammation in asthma: Current knowledge and
therapeutic implications. Clin Exp Allergy. 47:161–175.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Stokes JR and Casale TB: Characterization
of asthma endotypes: Implications for therapy. Ann. Allergy Asthma
Immunol. 117:121–125. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sze E, Bhalla A and Nair P: Mechanisms and
therapeutic strategies for non-T2 asthma. Allergy. 75:311–325.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
McGregor MC, Krings JG, Nair P and Castro
M: Role of biologics in asthma. Am J Respir Crit Care Med.
199:433–445. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Krings JG, McGregor MC, Bacharier LB and
Castro M: Biologics for severe asthma: Treatment-specific effects
are important in choosing a specific agent. J Allergy Clin Immunol
Pract. 7:1379–1392. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tan R, Liew MF, Lim HF, Leung BP and Wong
WSF: Promises and challenges of biologics for severe asthma.
Biochem Pharmacol. 179(114012)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Eger KA and Bel EH: The emergence of new
biologics for severe asthma. Curr Opin Pharmacol. 46:108–115.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pavord ID, Beasley R, Agusti A, Anderson
GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy
JV, et al: After asthma: Redefining airways diseases. Lancet.
391:350–400. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rogliani P, Calzetta L, Matera MG, Laitano
R, Ritondo BL, Hanania NA and Cazzola M: Severe asthma and
biological therapy: When, which, and for whom. Pulm Ther. 6:47–66.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
De Ferrari L, Chiappori A, Bagnasco D,
Riccio AM, Passalacqua G and Canonica GW: Molecular phenotyping and
biomarker development: Are we on our way towards targeted therapy
for severe asthma? Expert Rev Respir Med. 10:29–38. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kuruvilla ME, Lee FE and Lee GB:
Understanding asthma phenotypes, endotypes, and mechanisms of
disease. Clin Rev Allergy Immunol. 56:219–233. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bernstein JA and Panettieri R Jr:
Treatment of severe, uncontrolled eosinophilic asthma: Where we are
heading. J Asthma. 56:459–472. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Voehringer D, Reese TA, Huang X, Shinkai K
and Locksley RM: Type 2 immunity is controlled by IL-4/IL-13
expression in hematopoietic non-eosinophil cells of the innate
immune system. J Exp Med. 203:1435–1446. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chang YJ, Kim HY, Albacker LA, Baumgarth
N, McKenzie AN, Smith DE, Dekruyff RH and Umetsu DT: Innate
lymphoid cells mediate influenza-induced airway hyper-reactivity
independently of adaptive immunity. Nat Immunol. 12:631–638.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
King GG, James A, Harkeness L and Warki P:
Pathophysiology of severe asthma: We've only just started.
Respirology. 23:262–271. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Brusselle GG, Maes T and Bracke KR:
Eosinophils in the spotlight: Eosinophilic airway inflammation in
nonallergic asthma. Nat Med. 19:977–979. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bakakos A, Loukides S and Bakakos P:
Severe eosinophilic asthma. J Clin Med. 8(1375)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dunican EM, Elicker BM, Gierada DS, Nagle
SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Scroggins ME, Di
Maio S, Hoffman EA, et al: Mucus plugs in patients with asthma
linked to eosinophilia and airflow obstruction. J Clin Invest.
128:997–1009. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schulman ES: Development of a monoclonal
anti-immunoglobulin E antibody (omalizumab) for the treatment of
allergic respiratory disorders. Am J Respir Crit Care Med.
164:S6–S11. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Busse WW, Morgan WJ, Gergen PJ, Mitchell
HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic
JA, et al: Randomized trial of omalizumab (anti-IgE) for asthma in
inner-city children. N Engl J Med. 364:1005–1015. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hanania NA, Alpan O, Hamilos DL, Condemi
JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA and Busse
W: Omalizumab in severe allergic asthma inadequately controlled
with standard therapy: A randomized trial. Ann Intern Med.
154:573–582. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hanania NA, Wenzel S, Rosén K, Hsieh HJ,
Mosesova S, Choy DF, Lal P, Arron JR, Harris JM and Busse W:
Exploring the effects of omalizumab in allergic asthma: An analysis
of biomarkers in the EXTRA study. Am J Respir Crit Care Med.
187:804–811. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ledford D, Busse W, Trzaskoma B, Omachi
TA, Rosén K, Chipps BE, Luskin AT and Solari PG: A randomized
multicenter study evaluating Xolair persistence of response after
long-term therapy. J Allergy Clin Immunol. 140:162–169.e2.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Humbert M, Taillé C, Mala L, Le Gros V,
Just J and Molimard M: STELLAIR investigators. Omalizumab
effectiveness in patients with severe allergic asthma according to
blood eosinophil count: The STELLAIR study. Eur Respir J.
51(1702523)2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Casale TB, Luskin AT, Busse W, Zeiger RS,
Trzaskoma B, Yang M, Griffin NM and Chipps BE: Omalizumab
effectiveness by biomarker status in patients with asthma: Evidence
from PROSPERO, a prospective real-world study. J Allergy Clin
Immunol Pract. 7:156–164.e1. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Esquivel A, Busse WW, Calatroni A, Togias
AG, Grindle KG, Bochkov YA, Gruchalla RS, Kattan M, Kercsmar CM,
Khurana Hershey G, et al: Effects of omalizumab on rhinovirus
infections, illnesses, and exacerbations of asthma. Am J Respir
Crit Care Med. 196:985–992. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Gill MA, Liu AH, Calatroni A, Krouse RZ,
Shao B, Schiltz A, Gern JE, Togias A and Busse WW: Enhanced
plasmacytoid dendritic cell antiviral responses after omalizumab. J
Allergy Clin Immunol. 141:1735–1743.e9. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Busse W: Biological treatments for severe
asthma: Where do we stand? Curr Opin Allergy Clin Immunol.
18:509–518. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Mavissakalian M and Brady S: The current
state of biologic therapies for treatment of refractory asthma.
Clinic Rev Allerg Immunol. 59:195–207. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xolair® Full Prescribing
Information. Genentech. March 21, 2014. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf.
Accessed August 12, 2021.
|
|
38
|
Leckie MJ, ten Brinke A, Khan J, Diamant
Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF,
Djukanovic R, et al: Effects of an interleukin-5 blocking
monoclonal antibody on eosinophils, airway hyper-responsiveness,
and the late asthmatic response. Lancet. 356:2144–2148.
2000.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Nucala® Full Prescribing
Information. GlaxoSmithKline. September 2019. Available from:
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF.
Accessed August 12, 2021.
|
|
40
|
Pavord ID, Korn S, Howarth P, Bleecker ER,
Buhl R, Keene ON, Ortega H and Chanez P: Mepolizumab for severe
eosinophilic asthma (DREAM): A multicentre, double-blind,
placebo-controlled trial. Lancet. 380:651–659. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ortega HG, Liu MC, Pavord ID, Brusselle
GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey
SW, et al: Mepolizumab treatment in patients with severe
eosinophilic asthma. N Engl J Med. 371:1198–1207. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Bel EH, Wenzel SE, Thompson PJ, Prazma CM,
Keene ON, Yancey SW, Ortega HG and Pavord ID: SIRIUS Investigators.
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic
asthma. N Engl J Med. 371:1189–1197. 2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lugogo N, Domingo C, Chanez P, Leigh R,
Gilson MJ, Price RG, Yancey SW and Ortega HG: Long-term efficacy
and safety of mepolizumab in patients with severe eosinophilic
asthma: A multi-center, open-label, phase III study. Clin Ther.
38:2058–2070.e1. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
US Food, Drug Administration: CINQAIR
(reslizumab) Injection, for Intravenous Use. Reference ID: 3906489,
2016.
|
|
45
|
European Medicines Agency.
EMA/450050/2016. EMEA/H/C/003912. EPAR summary for the public.
CINQAERO. INN - reslizumab. https://www.ema.europa.eu/en/documents/overview/cinqaero-epar-summary-public_en.pdf,
Accessed May 19, 2021.
|
|
46
|
Corren J, Weinstein S, Janka L, Zangrilli
J and Garin M: Phase 3 study of reslizumab in patients with poorly
controlled asthma: Effects across a broad range of eosinophil
counts. Chest. 150:799–810. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Castro M, Zangrilli J, Wechsler ME,
Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C
and Korn S: Reslizumab for inadequately controlled asthma with
elevated blood eosinophil counts: Results from two multicentre,
parallel, double-blind, randomised, placebo-controlled, phase 3
trials. Lancet Respir Med. 3:355–366. 2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Murphy K, Jacobs J, Bjermer L, Fahrenholz
JM, Shalit Y, Garin M, Zangrilli J and Castro M: Long-term safety
and efficacy of reslizumab in patients with eosinophilic asthma. J
Allergy Clin Immunol Pract. 5:1572–1581.e3. 2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kolbeck R, Kozhich A, Koike M, Peng L,
Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW,
Stephens GL, et al: MEDI-563, a humanized anti-IL-5 receptor alpha
mAb with enhanced antibody-dependent cell-mediated cytotoxicity
function. J Allergy Clin Immunol. 125:1344–1353.e2. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Pham TH, Damera G, Newbold P and Ranade K:
Reductions in eosinophil biomarkers by benralizumab in patients
with asthma. Respir Med. 111:21–29. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
US Food, Drug Administration: FASENRA
(benralizumab) injection, for subcutaneous use. Reference ID:
4181236, 2019.
|
|
52
|
European Medicines Agency: EMEA/H/C/4433,
2019. www.ema.europa.eu/en/documents/overview/fasenra-epar-medicine-overview_en.pdf.
Accessed 10 May 2021.
|
|
53
|
Bleecker ER, FitzGerald JM, Chanez P, Papi
A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M,
Werkström V, et al: Efficacy and safety of benralizumab for
patients with severe asthma uncontrolled with high-dosage inhaled
corticosteroids and long-acting β2-agonists (SIROCCO): A
randomised, multicentre, placebo-controlled phase 3 trial. Lancet.
388:2115–2127. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
FitzGerald JM, Bleecker ER, Nair P, Korn
S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule
S, et al: Benralizumab, an anti-interleukin-5 receptor α monoclonal
antibody, as add-on treatment for patients with severe,
uncontrolled, eosinophilic asthma (CALIMA): A randomised,
double-blind, placebo-controlled phase 3 trial. Lancet.
388:2128–2141. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Nair P, Wenzel S, Rabe KF, Bourdin A,
Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S and Goldman
M: ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of
benralizumab in severe asthma. N Engl J Med. 376:2448–2458.
2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Busse WW, Bleecker ER, FitzGerald JM,
Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ and Goldman
M: BORA study investigators. Long-term safety and efficacy of
benralizumab in patients with severe, uncontrolled asthma: 1-year
results from the BORA phase 3 extension trial. Lancet Respir Med.
7:46–59. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
US Food, Drug Administration. DUPIXENT
(dupilumab) injection, for subcutaneous use, 2017. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf.
Accessed December 11, 2020.
|
|
58
|
European Medicines Agency. Dupinex:
EMEA/H/C/004390, 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent.
Accessed December 1, 2020.
|
|
59
|
Wenzel S, Castro M, Corren J, Maspero J,
Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, et
al: Dupilumab efficacy and safety in adults with uncontrolled
persistent asthma despite use of medium-to-high-dose inhaled
corticosteroids plus a long-acting β2 agonist: A randomised
double-blind placebo-controlled pivotal phase 2b dose-ranging
trial. Lancet. 388:31–44. 2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Castro M, Corren J, Pavord ID, Maspero J,
Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al:
Dupilumab efficacy and safety in moderate-to-severe uncontrolled
asthma. N Engl J Med. 378:2486–2496. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Rabe KF, Nair P, Brusselle G, Maspero JF,
Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, et al:
Efficacy and safety of dupilumab in glucocorticoid-dependent severe
asthma. N Engl J Med. 378:2475–2485. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Corren J, Castro M, Ford LB, Bernstein JA,
Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, et
al: Dupilumab improves asthma outcomes irrespective of frequency of
previous asthma exacerbation history. Ann Allergy Asthma Immunol.
123:222–224.e1. 2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Corren J, Castro M, O'Riordan T, Hanania
NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice
MS, et al: Dupilumab efficacy in patients with uncontrolled,
moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract.
8:516–526. 2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Dupixent® Full Prescribing
Information. Regeneron Sanofi Genzyme. January 2021. Available
from: https://www.regeneron.com/downloads/dupixent_fpi.pdf.
Accessed August 12, 2021.
|
|
65
|
Ultsch M, Bevers J, Nakamura G, Vandlen R,
Kelley RF, Wu LC and Eigenbrot C: Structural basis of signaling
blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol.
425:1330–1339. 2013.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Corren J, Lemanske RF, Hanania NA,
Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC,
Su Z, et al: Lebrikizumab treatment in adults with asthma. N Engl J
Med. 365:1088–1098. 2011.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Hanania NA, Noonan M, Corren J, Korenblat
P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H,
et al: Lebrikizumab in moderate-to-severe asthma: Pooled data from
two randomised placebo-controlled studies. Thorax. 70:748–756.
2015.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Piper E, Brightling C, Niven R, Oh C,
Faggioni R, Poon K, She D, Kell C, May RD, Geba GP and Molfino NA:
A phase II placebo-controlled study of tralokinumab in
moderate-to-severe asthma. Eur Respir J. 41:330–338.
2013.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Brightling CE, Chanez P, Leigh R, O'Byrne
PM, Korn S, She D, May RD, Streicher K, Ranade K and Piper E:
Efficacy and safety of tralokinumab in patients with severe
uncontrolled asthma: A randomised, double-blind,
placebo-controlled, phase 2b trial. Lancet Respir Med. 3:692–701.
2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Corren J, Parnes JR, Wang L, Mo M, Roseti
SL, Griffiths JM and van der Merwe R: Tezepelumab in adults with
uncontrolled asthma. N Engl J Med. 377:936–946. 2017.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Menzies-Gow A, Colice G, Griffiths JM,
Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist Å,
Mo M and Garcia Gil E: NAVIGATOR: A phase 3 multicentre,
randomized, double-blind, placebo-controlled, parallel-group trial
to evaluate the efficacy and safety of tezepelumab in adults and
adolescents with severe, uncontrolled asthma. Respir Res.
21(266)2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Weschler ME, Colice G, Griffiths JM,
Almqvist G, Skärby T, Piechowiak T, Kaur P, Bowen K, Hellqvist Å,
Mo M and Garcia Gil E: SOURCE: A phase 3, multicentre, randomized,
double-blind, placebo-controlled, parallel group trial to evaluate
the efficacy and safety of tezepelumab in reducing oral
corticosteroid use in adults with oral corticosteroid dependent
asthma. Respir Res. 21(264)2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Menzies-Gow A, Ponnarambil S, Downie J,
Bowen K, Hellqvist Å and Colice G: DESTINATION: A phase 3,
multicentre, randomized, double-blind, placebo-controlled,
parallel-group trial to evaluate the long-term safety and
tolerability of tezepelumab in adults and adolescents with severe,
uncontrolled asthma. Respir Res. 21(279)2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Dinarello CA: Immunological and
inflammatory functions of the interleukin-1 family. Annu Rev
Immunol. 27:519–550. 2009.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Gabryelska A, Kuna P, Antczak A,
Białasiewicz P and Panek M: IL-33 mediated inflammation in chronic
respiratory diseases-understanding the role of the member of IL-1
superfamily. Front Immunol. 10(692)2019.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Efficacy and safety study of GSK3772847 in
subjects with moderately severe asthma. ClinicalTrials.gov Identifier: NCT03207243,
https://clinicaltrials.gov/ct2/show/NCT03207243.
Accessed August 12, 2020.
|
|
77
|
Study of REGN3500 and dupilumab in
patients with asthma. ClinicalTrials.gov Identifier: NCT03112577,
https://clinicaltrials.gov/ct2/show/NCT03112577.
Accessed August 12, 2020.
|
|
78
|
Dantes E, Fildan AP, Toma CL, Voicu GH and
Oancea C: Respiratory impact in workers exposed to air pollutants
from petroleum refinery. J Environ Prot Ecol. 17:523–531. 2016.
|
|
79
|
Tofolean D, Popescu G, Arghir IA, Frandes
M and Fildan AP: A different aproach of chronic obstructive
pulmonary disease severity and plastic medical devices used for
oxygenotherapy. Mater Plast. 56:295–230. 2019.
|
|
80
|
Barsan M, Rajnoveanu AG, Cocarla A, Bolfa
P, Login CC, Socaciu AI, Decea N and Leucuta DC: A study of
oxidative stress and pulmonary damage after silica instillation in
rats and the effect of curcumin administration. Med Pr. 72:239–247.
2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Trenchea M, Arghir IA, Popescu GG, Rascu
S, Bechir ES, Tofolean DE, Fildan AP, Ion I and Dantes E: The triad
nocturia, smoking and obstructive sleep apnea. Rev Chim.
70:1839–1842. 2019.
|
|
82
|
Chung KF, Wenzel SE, Brozek JL, Bush A,
Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et
al: International ERS/ATS guidelines on definition, evaluation and
treatment of severe asthma. Eur Respir J. 43:343–373.
2014.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Hogea Stanca P, Tudorache E, Fildan AP,
Fira-Mladinescu O, Marc M and Oancea C: Risk factors of chronic
obstructive pulmonary disease exacerbations. Clin Respir J.
14:183–197. 2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Bourdin A, Husereau D, Molinari N, Golam
S, Siddiqui MK, Lindner L and Xu X: Matching-adjusted indirect
comparison of benralizumab versus interleukin-5 inhibitors for the
treatment of severe asthma: A systematic review. Eur Respir J.
52(1801393)2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Casale TB, Pacou M, Mesana L, Farge G, Sun
SX and Castro M: Reslizumab compared with benralizumab in patients
with eosinophilic asthma: A systematic literature review and
network meta-analysis. J Allergy Clin Immunol Pract. 7:122–130.e1.
2019.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Busse W, Chupp G, Nagase H, Albers FC,
Doyle S, Shen Q, Bratton DJ and Gunsoy NB: Anti-IL-5 treatments in
patients with severe asthma by blood eosinophil thresholds:
Indirect treatment comparison. J Allergy Clin Immunol.
143:190–200.e20. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Calzetta L, Matera MG and Rogliani P:
Monoclonal antibodies in severe asthma: Is it worth it? Expert Opin
Drug Metab Toxicol. 15:517–520. 2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Edris A, De Feyter S, Maes T, Joos G and
Lahousse L: Monoclonal antibodies in type 2 asthma: A systematic
review and network meta-analysis. Respir Res.
20(179)2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Albers F, Liu MC, Chipps BE, Chapman KR,
Muñoz X, Bergna M, Devouassoux G, Azmi J, Price R and Galkin D:
Therapeutic switch from omalizumab to mepolizumab in patients with
uncontrolled severe eosinophilic asthma: Treatment effect by prior
omalizumab treatment duration. J Allergy Clin Immunol. 143 (Suppl
2)(AB102)2019.
|
|
90
|
Pérez de Llano LA, Cosío BG, Domingo C,
Urrutia I, Bobolea I, Valero A, Entrenas Costa LM, Quirce S,
Barranco P, Marina Malanda N, et al: Efficacy and safety of
reslizumab in patients with severe asthma with inadequate response
to omalizumab: A multicenter, open-label pilot study. J Allergy
Clin Immunol Pract. 7:2277–2283.e2. 2019.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Kavanagh J, Green L, Fernandes M, Roxas C,
Kent BD, Jackson DJ and d'Ancona G: Response to benralizumab after
sub-optimal response to mepolizumab in oral corticosteroid
dependent severe eosinophilic asthma. Am J Respir Crit Care Med.
199(A2675)2019.
|
|
92
|
Haldar P, Brightling CE, Singapuri A,
Hargadon B, Gupta S, Monteiro W, Bradding P, Green RH, Wardlaw AJ,
Ortega H and Pavord ID: Outcomes after cessation of mepolizumab
therapy in severe eosinophilic asthma: A 12-month follow-up
analysis. J Allergy Clin Immunol. 133:921–923. 2014.PubMed/NCBI View Article : Google Scholar
|
